title: [Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].
abstract: OBJECTIVE
  To explore the efficiency and toxicity of non-myeloablative stem cell transplantation (NAST) for hematological disease.
  
  
  METHODS
  Seventeen patients, including 3 acute myeloid leukemia, 6 chronic myelogenous leukemia, 4 severe aplastic anemia, 2 non-Hodgkin's lymphoma, 1 multiple myeloma and 1 myelodysplastic syndromes received NAST from HLA-identical sibling donors. Peripheral blood stem cells were mobilized by G-CSF 300 microg/12 hours x 5 d. (2.15 -10.01) x 10(6) CD(34)(+) cells/kg were transplanted. A non-myeloablative conditioning regimen included fludarabine 30 mg.m(-2).d(-1) x 6 d;busulfan 4 mg.kg(-1).d(-1) x 2 d or cyclophosphamide 50 mg.kg(-1).d(-1) x 2 d and antilymphocytic globulin 12 approximately 15 mg.kg(-1).d(-1) x 4 d. Cyclosporin A was used to prevent graft versus host disease (GVHD) alone and no G-CSF was administered after NAST.
  
  
  RESULTS
  Hematopoiesis reconstitution resumed on day 8 to day 19 (average of day 13). Severe mucositis was absent. Hepatic venoocclusive disease did not occur. Infectious complications were rare. Acute and chronic GVHD each occurred in 5 patients. Idiopathic pneumonia was developed in 5 patients. In the follow-up duration of 120 to 425 days, 16 of the 17 cases had a stable mixed or complete chimerical states. Fourteen of 17 patients are alive.
  
  
  CONCLUSIONS
  NAST is an effective therapy in the treatment of hematological diseases with less complications, less blood transfusion and lower cost.
authors.affiliation: First Affiliated Hospital, Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, China.
authors.forename: De-pei
authors.initials: DP
authors.lastname: Wu
authors.forename: Xiao
authors.initials: X
authors.lastname: Ma
authors.forename: Ai-ning
authors.initials: AN
authors.lastname: Sun
authors.forename: Zheng-zheng
authors.initials: ZZ
authors.lastname: Fu
authors.forename: Xiao-wen
authors.initials: XW
authors.lastname: Tang
authors.forename: Hui-ying
authors.initials: HY
authors.lastname: Qiu
authors.forename: Miao
authors.initials: M
authors.lastname: Miao
authors.forename: Yue-jun
authors.initials: YJ
authors.lastname: Liu
authors.forename: Cai-xia
authors.initials: CX
authors.lastname: Li
authors.forename: Xue-ming
authors.initials: XM
authors.lastname: Xia
authors.forename: Bao-jue
authors.initials: BJ
authors.lastname: Lin
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; C024352:fludarabine